Quoin Pharmaceuticals Doses First Patient in Rare Disease Trial

Quoin Pharmaceuticals (Nasdaq:QNRX), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases has dosed the first patient in a clinical trial evaluating a treatment for Netherton Syndrome.

The company has announced it will initiate a second study assessing its QRX003 topical lotion in Netherton patients who are currently receiving off-label treatment including systemic therapy for symptomatic relief. This second study has now been cleared by the FDA to initiate clinical testing.


  • Quoin’s six target clinical sites are on track to be fully opened by year end.
  • More than 70 potential clinical trial candidates have already progressed through the company’s initial screening process.
  • Second study evaluating QRX003 for Netherton Syndrome has been cleared by the FDA. The study will evaluate 10 Netherton patients over a 12-week period.
  • Quoin believes that QRX003 has the potential to become the standard of care for Netherton patients.

To find out more about Quoin’s clinical trial, please visit: https://www.nethertonsyndromeclinicaltrials.com.


This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

Share This Article


About the Author

Quoin Pharmaceuticals Doses First Patient in Rare Disease Trial

Editor Prism MarketView